OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
QTTB
Q32 Bio Inc.
There isn't enough reported data to score QTTB yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
QTTB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Strong |
QTTB's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over QTTB in the historical PE scenario, which offers more potential upside but is not a forecast.
QTTB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.4x | $8.37 | -5.2% |
| Current | 2.6x | $8.82 | — |
| Fair | 2.9x | $10.05 | +14% |
| Expensive | 4.8x | $16.68 | +89% |
Historical ranges are pointers, not guarantees.
QTTB's PE is 2.5x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
QTTB Forward outlook
There aren't enough analyst estimates for QTTB to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus QTTB down 75%.
QTTB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$14.07 | +$26.61 |
| Q2 2024 | -$22.87 | +$18.17 |
| Q1 2024 | -$32.43 | +$6.81 |
| Q4 2023 | -$35.10 | -$33.48 |
| Q3 2023 | -$40.68 | -$38.16 |
| Q2 2023 | -$41.04 | -$39.42 |
| Q1 2023 | -$39.24 | -$37.08 |
| Q4 2022 | -$1.62 | +$29.52 |
QTTB has returned to profit: it earned $3.46 per share over the past year, after losing money the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
QTTB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $354K | -56% |
| Q1 2023 | $802K | 0% |
| Q4 2022 | $802K | 0% |
| Q3 2022 | $802K | -52% |
| Q2 2022 | $802K | -63% |
| Q1 2022 | $802K | -97% |
| Q4 2021 | $802K | -18% |
| Q3 2021 | $1.7M | +196% |
QTTB's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -8705% | -5176 points |
| Q1 2023 | -3430% | +1260 points |
| Q4 2022 | -4301% | -108 points |
| Q3 2022 | -4098% | -2269 points |
| Q2 2022 | -3530% | -2133 points |
| Q1 2022 | -4691% | -4687 points |
| Q4 2021 | -4193% | -1152 points |
| Q3 2021 | -1828% | +3158 points |
QTTB's operating margin was −8705% last quarter, down 5176 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with QTTB at up 78%.
QTTB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.3M | +$6.1M |
| Q4 2025 | -$6.2M | +$5.3M |
| Q3 2025 | -$4.2M | +$15.4M |
| Q1 2025 | -$12.5M | +$2.1M |
| Q4 2024 | -$11.4M | +$10.1M |
| Q3 2024 | -$19.6M | +$5.4M |
| Q2 2024 | -$22.2M | +$1.4M |
| Q1 2024 | -$14.6M | +$11.7M |
QTTB has burned cash in almost every quarter: −$20M over the past year, against −$66M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over QTTB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
QTTB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +67% | +13.7M shares |
| 1 year | +178% | +21.8M shares |
| 3 years | +960% | +30.8M shares |
| 5 years | +984% | +30.9M shares |
| Available history | +1354% | +31.7M shares |
QTTB has 34M diluted shares, up 178% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
QTTB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.4x | Net Cash |
| Q2 2026 | -4.9x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
QTTB has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
QTTB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 17.7 | Oversold |
QTTB's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
QTTB PE vs Healthcare Sector
| Metric | QTTB | Sector median | Relative |
|---|---|---|---|
| PE | 2.6x | 26x | 90% below |
| PE % | 20 | 29 | 9 pts below |
QTTB has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over QTTB on trend strength, trading above more of its moving averages.
QTTB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.56 | 3% above |
| 20 week MA | $11.7 | 25% below |
| 50 week MA | $8.31 | 6.1% above |
| 100 week MA | $5.29 | 67% above |
| 200 week MA | $14.3 | 38% below |
QTTB's trend is mixed: it's above three of its five weekly moving averages, and 38% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.
QTTB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.6 | $227.7 | -41% |
| 2021 | $227.7 | $74.5 | -67% |
| 2022 | $74.5 | $21.4 | -71% |
| 2023 | $21.4 | $10.9 | -49% |
| 2024 | $10.9 | $3.36 | -69% |
| 2025 | $3.36 | $3.20 | -4.8% |
| 2026 YTD | $3.20 | $8.82 | +176% |
QTTB has the edge over OSCR on returns for 2026, with the stronger performance.